IN CASE YOU MISSED IT: This week, the chorus of evidence and support for patent reform has grown even larger with three important news items that demonstrate both the extent of Big Pharma’s patent abuse and the much-needed relief that substantive patent reform will bring American patients. Axios published the below article yesterday keying off […]

WHAT YOU NEED TO KNOW: USA Today Editorial Board: How Big Pharma Plays Games With Drug Patents And How To Combat It President Donald Trump came into office promising to do something about the inflated prices Americans pay for prescription drugs. He considered limiting rebates to the middlemen between insurance plans and drug companies but […]

IN CASE YOU MISSED IT: The New York Times published the op-ed below on Saturday acknowledging the role patent abuse plays in the drug pricing crisis that faces American consumers. This op-ed reinforces what CAPA has been telling lawmakers, that Big Pharma’s abuse of the patent system is hurting patients across the nation. “There is a […]

WHAT YOU NEED TO KNOW: In an important step toward reining in Big Pharma, the Senate Judiciary Committee approved yesterday the bipartisan Affordable Prescriptions for Patients Act, sponsored by U.S. Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), despite pushback from Big Pharma. Matthew Lane, executive director of the Coalition Against Patent Abuse: “We thank […]

As the Senate Judiciary Committee kicks off a third hearing today on the Tillis/Coons legislation, several Big Pharma advocates have once again made it onto the witness list. These Big Pharma companies have been abusing patent laws for years – keeping more affordable generic medications off the market and out of the hands of patients. […]

  Humira is a medicine that treats a number of conditions and is widely prescribed and used by millions of people around the world. It is the most profitable drug in history. Like many brand name drugs, it is also very expensive, but it is particularly expensive here in the U.S. In fact, in Europe […]